# A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers

> **NCT05363592** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CT-L01 12.5/500 mg
- **DRUG:** Alogliptin Benzoate 12.5 mg
- **DRUG:** Metformin HCl XR 500 mg

## Key facts

- **NCT ID:** NCT05363592
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-25
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-25
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363592, "A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05363592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*